GOG-0268

Terminated

Return to Protocol Table

A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864, IND# 61010) in Combination with Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary

Principal Investigator

John H Farley

Status

Terminated

Closed to Accrual

January 6, 2014

Closed to Accrual & Treatment

January 9, 2015

Complete

January 9, 2015

Terminated

April 19, 2022


Disease Site

Gynecologic [GY] Ovarian

Phase

II

Developmental Therapeutics

No

Primary Objective

To assess the activity of the study regimen as measured by the proportion of patients who are alive and progression-free for at least 12 months after study entry in patients with newly diagnosed Stage III or IV clear cell ovarian cancer in the following populations:

Patients in the U.S. and worldwide (outside of Japan)
 Patients in Japan

To compare progression-free survival in newly diagnosed Stage III or IV clear cell ovarian cancer patients in patients in the U.S. and worldwide (outside of Japan) versus patients in Japan.

Target Accrual

45

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.